Understanding tumor evolution in early-stage non-small cell lung cancer
A Multiomics Study of Tumor Evolution Characteristics and Prognostic Model in Early-stage Non-small Cell Lung Cancer
This study is trying to understand how early-stage non-small cell lung cancer changes over time by looking at tumor samples and DNA to help improve treatment and monitoring for patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Peking University People's Hospital Academic / other |
| Locations | 1 site (Beijing) |
| Trial ID | NCT05352035 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the evolutionary mechanisms of early-stage non-small cell lung cancer (NSCLC) through multiomics analysis. By analyzing tumor tissue and circulating tumor DNA, the study seeks to establish a prognostic model and a recurrence monitoring system. The findings could enhance the management of lung cancer patients and improve their overall prognosis. The study will utilize available clinical-pathologic data, imaging data, and follow-up information to support its objectives.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with early-stage NSCLC who have undergone radical surgical resection.
Not a fit: Patients with a history of other malignant tumors or evidence of distant metastasis prior to surgery may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prognostic models and monitoring systems for early-stage NSCLC patients.
How similar studies have performed: While multiomics approaches are gaining traction, this specific study's focus on early-stage NSCLC and its prognostic implications is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥ 18 years old; 2. Early-stage NSCLC patients underwent radical surgical resection; 3. Sufficient tumor tissue and blood sample for study use; 4. Available clinical-pathologic data, imaging data and follow-up date; 5. Written informed consent. Exclusion Criteria: 1. History of other malignant tumors; 2. Evidence of distant metastasis before surgery; 3. Insufficient tumor tissue or blood sample for study use; 4. Clinical-pathologic data, imaging data or follow-up date is not available; 5. Other judgments by the Investigator that the patient should not participate in the study.
Where this trial is running
Beijing
- Peking University People's Hospital — Beijing, China (Recruiting)
Study contacts
- Study coordinator: Kezhong Chen, M.D.
- Email: chenkezhong@pkuph.edu.cn
- Phone: +86-010-88326657
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.